Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for CML patients with Hard-to-Treat mutation?

NCT ID NCT06514534

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the drug asciminib in 20 adults with chronic myeloid leukemia who have a specific genetic change (T315I mutation) and cannot take the standard drug ponatinib. The goal is to see if asciminib can control the leukemia and improve outcomes. Participants take asciminib pills twice a day, and the study will measure how well the cancer responds after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
asciminib (Scemblix®)
What this could lead to
If successful, asciminib could offer a new treatment option for CML patients with the T315I mutation who have run out of other therapies.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive leukemia, myeloid, accelerated-phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA (CML)

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Bordeaux, 33076, France

  • Novartis Investigative Site

    RECRUITING

    Lille, 59037, France

  • Novartis Investigative Site

    RECRUITING

    Lyon, 69373, France

  • Novartis Investigative Site

    RECRUITING

    Nantes, 44093, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75475, France

  • Novartis Investigative Site

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.